Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Payables (2021 - 2025)

Historic Payables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $6.1 million.

  • Kiniksa Pharmaceuticals International's Payables fell 2615.27% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 2615.27%. This contributed to the annual value of $2.0 million for FY2024, which is 7527.29% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Payables is $6.1 million, which was down 2615.27% from $9.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Payables' 5-year high stood at $9.0 million during Q2 2025, with a 5-year trough of $648000.0 in Q2 2023.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Payables averaged around $4.1 million, with its median value being $2.8 million (2021).
  • Within the past 5 years, the most significant YoY rise in Kiniksa Pharmaceuticals International's Payables was 104089.51% (2024), while the steepest drop was 7527.29% (2024).
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Payables (Quarter) stood at $1.9 million in 2021, then soared by 322.86% to $7.9 million in 2022, then rose by 4.39% to $8.2 million in 2023, then plummeted by 75.27% to $2.0 million in 2024, then soared by 201.62% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $9.0 million for Q2 2025, and $2.0 million during Q1 2025.